52.36

7.38% 3.60

Spruce Biosciences Inc (SPRB)

Overview News Price History Financials Discussions Forecast

Spruce Biosciences Inc stock is traded at $52.36, with a volume of 171.01K. It is up +7.38% in the last 24 hours and up +1.85% over the past month. Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.

Previous Close:

$48.76

Open:

$49.48

24h Volume:

171.01K

Relative Volume:

2.61

Market Cap:

$144.11M

Revenue:

$697.00K

Net Income/Loss:

$-37.19M

P/E Ratio:

-1.389

EPS:

-37.6952

Net Cash Flow:

$-29.34M

1W Performance:

+6.63%

1M Performance:

+1.85%

6M Performance:

-31.80%

1Y Performance:

-90.34%

1-Day Range:

$49.48

$52.90

1-Week Range:

$46.49

$53.25

52-Week Range:

$7.26

$543.38

Spruce Biosciences Inc Stock (SPRB) Company Profile

Name

Spruce Biosciences Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

(415) 655-4168

Address

611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2026-05-19

Latest SEC Filings

SPRB's Discussions on Twitter

Compare SPRB vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SPRB Spruce Biosciences Inc	52.36	144.11M	697.00K	-37.19M	-29.34M	-37.70
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-27-26	Initiated	Craig Hallum	Buy
Dec-23-25	Initiated	Oppenheimer	Outperform
Dec-03-25	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-28-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Dec-11-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-11-24	Downgrade	Oppenheimer	Outperform → Perform
Mar-14-24	Downgrade	Guggenheim	Buy → Neutral
Mar-14-24	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-14-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-14-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-14-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-21-24	Initiated	Guggenheim	Buy
Dec-17-21	Initiated	Oppenheimer	Outperform
Dec-10-21	Initiated	The Benchmark Company	Speculative Buy
Nov-16-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-19-21	Initiated	H.C. Wainwright	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Nov-03-20	Initiated	Cowen	Outperform
Nov-03-20	Initiated	Credit Suisse	Outperform
Nov-03-20	Initiated	RBC Capital Mkts	Outperform
Nov-03-20	Initiated	SVB Leerink	Outperform

View All

Spruce Biosciences Inc Stock (SPRB) Latest News

Jun 18, 2026